EMBL Agri-Tech Partnership to deliver safe food and environmental health
The partnership will address global food security challenges through optimised agricultural research and data-driven innovation.
CONNECTIONS2024
connections
EMBL Science Day with Evonik: fostering collaborative innovations
EMBL hosted a Science Day with Evonik, bringing together 16 industry experts and EMBL scientists to explore collaborative research opportunities.
CONNECTIONS2024
connections
EMBL and Nikon launch tech development partnership for next-generation research
EMBL and Nikon have formally broadened their partnership to accelerate development of next-generation microscopy technologies.
EMBL ANNOUNCEMENTS2024
embl-announcements
Academia meets Industry: merging worlds through science
EMBL’s first Industry Day offered EMBL scientists a unique opportunity to network with several leading life science companies.
CONNECTIONS2024
connections
2024 EMBL Alumni Award recipients announced
Two former EMBL scientists have been recognised for their outstanding contributions to research and leadership capabilities in the fields of evolutionary cell biology and molecular medicine.
EMBL ANNOUNCEMENTS2024
alumniembl-announcements
‘X-ray vision’ for investigation of mRNA nanomedicines
EMBL Hamburg, Johannes Gutenberg University Mainz, Postnova Analytics GmbH, and BioNTech SE have developed a new method to quantitatively investigate sizes of nanoparticles containing mRNA. It may become an important part of regular characterisation of mRNA nanomedicines in the future.
SCIENCE & TECHNOLOGY2023
sciencescience-technology
Using artificial intelligence to discover therapeutic antibodies
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
SCIENCE & TECHNOLOGY2023
sciencescience-technology
Hamburg collaboration paves the way to cleaner technologies for industry
An interdisciplinary collaboration between Hamburg scientists has yielded new insights into the structure and function of a heat-resistant enzyme from an exotic microbe. In this interview, EMBL Hamburg’s Matthias Wilmanns and TUHH’s Garo Antranikian discuss how their collaboration developed and…
SCIENCE & TECHNOLOGY2023
sciencescience-technology
Advocating for a generalist approach to science and life
Sara Fahs, who did her PhD from EMBL Heidelberg and is one of the newest members of the EMBL alumni association board, writes about key insights from her journey in science and her work on medicinal chemistry, during a career spanning academia and industry.
EMBLetc2023
mRNA nanomedicines scoop Nobel Prize in Physiology or Medicine
Pioneers of the mRNA nanomedicines technology receive 2023 Nobel Prize in Physiology or medicine. EMBL is pleased to have supported the development of the application of the mRNA nanomedicine technology through our long-standing collaboration with BioNTech, Johannes Gutenberg University Mainz and…
SCIENCE & TECHNOLOGY2023
sciencescience-technology
Welcome: David Hulcoop
David Hulcoop discusses how his experience bridging organisational cultures will help address critical challenges in drug discovery and target selection at Open Targets.
LAB MATTERSPEOPLE & PERSPECTIVES2023
announcementslab-matterspeople-perspectives
From academia to industry: exploring new career paths
EMBL organised a five-day summer school to help PhD students and postdocs learn more about research and development (R&D) related industry career roles.
LAB MATTERS2023
eventslab-matters
The power of cell sorting: understanding heart disease, phase separation, plankton, and more
EMBL researchers use a new cell sorting technology to gain new insights into cellular function in health and disease, as well as for other innovative applications.
SCIENCE & TECHNOLOGY2023
sciencescience-technology
David Hulcoop appointed as Open Targets Director
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
EMBL ANNOUNCEMENTS2023
announcementsembl-announcements
FAIRification framework: making your data Findable, Accessible, Interoperable, and Reusable
New framework to improve the FAIRness of clinical and molecular datasets
2023
perspectives
Supporting the development of hologenomic approaches for more sustainable animal feeds
HoloFood, the first consistent collection of multiomic data about chicken and salmon gut microbiomes, set to enable the development of better animal feeds.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
Vizgen joins EMBL science-industry programme
Vizgen, the life science company dedicated to improving human health by visualising single-cell spatial genomics information, has joined EMBL’s Corporate Partnership Programme.
CONNECTIONSLAB MATTERS2023
connectionslab-matters
Nikon Europe increases support for EMBL’s innovative scientific training programme
Nikon Europe has intensified its engagement with EMBL's Corporate Partnership Programme to support young scientists.
CONNECTIONSLAB MATTERS2023
connectionslab-matters
Sharing science, shaping opportunities for collaboration
An annual Corporate Partnership Programme meeting provided a forum for EMBL researchers and industry representatives to discuss mobile labs, planetary biology, and other areas of common interest.
CONNECTIONS2023
connectionsevents
Pfizer joins the Open Targets consortium
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
CONNECTIONS2022
announcementsconnectionsscience
Cell sorting enters a new dimension
EMBL researchers, in collaboration with BD Biosciences, have demonstrated a new technology that allows rapid image-based sorting of cells. The new technology represents a major upgrade to flow cytometry and has applications in diverse life science fields.
SCIENCE & TECHNOLOGY2022
sciencescience-technology
How structural biology helps to make RNA vaccines
RNA vaccines, such as the ones for COVID-19, represent a new approach in vaccine technology. Cy Jeffries, faculty staff scientist at EMBL Hamburg, explains the clever technology behind RNA vaccines, and how structural biology contributes to its development. EMBL Hamburg collaborated on several…
SCIENCE & TECHNOLOGY2021
sciencescience-technology
EMBL experimental services enable European researchers to tackle global societal challenges
Independent impact review finds EMBL experimental services are ‘critical’ for research and endorses EMBL as a world-class service provider for academia and industry.
LAB MATTERSSCIENCE & TECHNOLOGY2021
lab-mattersscience-technology
The PROTACtable genome – a new route to drug discovery
Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
SCIENCE & TECHNOLOGY2021
sciencescience-technology
Molecular biology stepping up to solve environmental challenges
EMBL’s EU Green Week event showcased various ways molecular biology research can help solve environmental challenges.
LAB MATTERS2021
lab-matters
New perspectives for treating psychiatric disorders
Scientists have determined the structure of Glycine Transporter 1. The finding could open new avenues for developing therapeutics for psychiatric disorders
SCIENCE & TECHNOLOGY2021
sciencescience-technology
EMBL facilities support development of RNA vaccines
Biotechnology company BioNTech and Johannes Gutenberg University Mainz conduct collaborative research with EMBL scientists at the beamline P12 in Hamburg
SCIENCE & TECHNOLOGY2020
sciencescience-technology
Life sciences open their doors for engineers
The European Molecular Biology Laboratory has secured 6.8 million Euros funding from the European Commission to launch a unique training programme. The ARISE Programme will train and develop Europe’s next generation leadership for research infrastructures in the life sciences.
LAB MATTERS2020
lab-matters
Antibody engineering for therapy and diagnosis
The new EMBL spinoff company Araxa Biosciences GmbH aims to set new standards for the development of antibody-based therapeutics and diagnostics
LAB MATTERSSCIENCE & TECHNOLOGY2020
lab-mattersscience-technology
EIPOD4: 2019 applications are open
EIPOD4 will prepare researchers for the increasing interdisciplinarity of scientific career paths
EMBL ANNOUNCEMENTSLAB MATTERS2019
embl-announcementslab-matters
Welcome: Jessica Vamathevan
Building bonds between academia and industry
LAB MATTERS2019
lab-matters
Miltenyi Biotec becomes new corporate partner
Joining forces to advance training in biomedical research and therapy
CONNECTIONSLAB MATTERS2019
connectionslab-matters
Discovering new enzymes just got easier
EMBL-EBI industry case study: Biocatalysts
SCIENCE & TECHNOLOGY2018
sciencescience-technology
Science in industry
EMBL postdocs discover industry-led research opportunities at the Corporate Summer School
LAB MATTERS2018
eventslab-matters
Sanofi joins Open Targets
Pharmaceutical company Sanofi strengthens drug targets discovery collaboration Open Targets
CONNECTIONSLAB MATTERS2018
connectionslab-matters
Promega joins EMBL’s Corporate Partnership Programme
EMBL and Promega collaborate to train young scientists
CONNECTIONSLAB MATTERS2018
connectionslab-matters
Open call for detector and imaging tech projects
The ATTRACT initiative, of which EMBL is a partner, has launched an open call for seed funding
EMBL ANNOUNCEMENTSLAB MATTERS2018
embl-announcementslab-matters
Roche joins EMBL’s Corporate Partnership Programme
Roche and EMBL join forces
CONNECTIONSLAB MATTERS2018
connectionslab-matters
PhD goals: why not start a company?
EMBL-EBI PhD student launches start-up focusing on epigenetics and wellbeing
LAB MATTERSPEOPLE & PERSPECTIVES2018
lab-matterspeople-perspectives
Celgene joins Open Targets
New partner strengthens drug discovery collaboration
CONNECTIONSLAB MATTERS2018
connectionslab-matters
EMBL spinoff to help antibody discovery
New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies
LAB MATTERSSCIENCE & TECHNOLOGY2018
lab-mattersscience-technology
10x Genomics joins EMBL’s Corporate Partnership Programme
Joining forces for single-cell research
CONNECTIONSLAB MATTERS2018
connectionslab-matters
Takeda joins drug target discovery initiative
Takeda joins pioneering public-private drug discover collaboration Open Targets
LAB MATTERSPEOPLE & PERSPECTIVES2017
lab-matterspeople-perspectives
EMBL and HeidelbergCement explore ways to reduce carbon
EMBL and HeidelbergCement sign Memorandum of Understanding
LAB MATTERSPEOPLE & PERSPECTIVES2017
lab-matterspeople-perspectives
UX toolkit aids industry R&D
Exploring the potential of user experience for life sciences through industry workshops
SCIENCE & TECHNOLOGY2017
eventsscience-technology
EMBL spin-off Luxendo acquired by Bruker
Accelerating researchers’ access to next-generation light-sheet microscopy
CONNECTIONSLAB MATTERS2017
connectionslab-matters
Pathways: Life science investment
EMBL alumnus Joep Muijrers talks about making the transition from science into business
PEOPLE & PERSPECTIVES2017
alumnipeople-perspectives
Turning up the heat on drug side effects
Side-effects of leukaemia drug explained, reveal possibility of repurposing to treat other diseases
SCIENCE & TECHNOLOGY2016
sciencescience-technology
Fundraising dimensions
Alumnus and entrepreneur Marc Zabeau speaks at inaugural Life Science Funders and Foundations event
CONNECTIONS2016
connectionsevents
Making business in Britain
Abel Ureta-Vidal and Louise Modis join colleagues and peers at gathering of UK-based alumni
CONNECTIONS2016
alumniconnections
Biogen joins CTTV
Pioneering target validation collaboration expands to accelerate drug discovery research.
CONNECTIONSLAB MATTERS2016
connectionslab-matters
How to make a protein happy
Protein screens developed at EMBL Hamburg now commercially available
SCIENCE & TECHNOLOGY2016
sciencescience-technology
Target Validation platform launches
Identifying evidence-based relationships between drug targets and diseases.
CONNECTIONSLAB MATTERS2015
connectionslab-matters
EIPOD goes cubic
EI3POD: flagship interdisciplinary postdoc programme opens its doors to academia and industry.
EMBL ANNOUNCEMENTSLAB MATTERS2015
embl-announcementslab-matters
Building bridges with BioStruct-X
Industrial partners and BioStruct-X facility members gather for Workshop at EMBL Hamburg.
CONNECTIONS2015
connectionsevents
Inside industry: Part I
Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.
LAB MATTERS2015
alumnilab-matters
Inside industry: Part II
Alumni in senior positions in industry share career challenges, highlights and EMBL’s continuing role.
LAB MATTERS2015
alumnilab-matters
Focusing on partnerships
EMBL’s corporate partners zoom in on big data and bioimaging.
2015
events
What can your synchrotron do for you?
Life Science Nord event reveals how pharmaceutical companies use synchrotrons for their research.
2014
events
Forty things that make EMBL – Part 2
As the Lab turns 40, staff and alumni share 40 things that make EMBL, EMBL
LAB MATTERS2014
lab-matters
Resourceful alumni
Two EMBL alumni, each developing community-led tools to support life science research
LAB MATTERS2014
alumnilab-matters
On target
A new EMBL-EBI biomedical initiative works to determine the best target proteins for new drugs.
CONNECTIONSLAB MATTERS2014
connectionslab-matters
EMBL coordinates new Marie Curie Research Training Network “Chromatin Plasticity”
The European Commission has awarded 3.7 Million Euro under the European Union Framework 6 Programme over the next four years to a new Marie Curie Research Training Network, coordinated by Dr. Andreas Ladurner at the European Molecular Biology Laboratory (EMBL). The long molecules of DNA that carry…
LAB MATTERS2007
lab-matters
EMBL scientists found start-up company to develop anti-cancer drugs
Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…
LAB MATTERSSCIENCE & TECHNOLOGY2006
lab-mattersscience-technology
No results found